This company listing is no longer active
Resumen de acción B8FE
A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Competidores de Biofrontera AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €2.26 |
| 52 Week High | €4.74 |
| 52 Week Low | €1.26 |
| Beta | 1.27 |
| 1 Month Change | 2.73% |
| 3 Month Change | 32.94% |
| 1 Year Change | -48.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.52% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| B8FE | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | -11.7% | -0.7% | -3.1% |
| 1Y | -48.6% | -18.1% | -0.5% |
Rentabilidad vs. Industria: B8FE underperformed the German Pharmaceuticals industry which returned -7.9% over the past year.
Rentabilidad vs. Mercado: B8FE underperformed the German Market which returned -25.6% over the past year.
Volatilidad de los precios
| B8FE volatility | |
|---|---|
| B8FE Average Weekly Movement | 31.8% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Precio estable de las acciones: B8FE's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: B8FE's weekly volatility has increased from 26% to 32% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1997 | 98 | Hermann Lubbert | www.biofrontera.com |
Resumen de fundamentos de Biofrontera AG
| Estadísticas fundamentales de B8FE | |
|---|---|
| Capitalización bursátil | €78.27m |
| Beneficios(TTM) | €10.45m |
| Ingresos (TTM) | €30.77m |
7.5x
Ratio precio-beneficio (PE)2.5x
Ratio precio-ventas (PS)¿Está B8FE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de B8FE | |
|---|---|
| Ingresos | €30.77m |
| Coste de los ingresos | €4.67m |
| Beneficio bruto | €26.10m |
| Otros gastos | €15.65m |
| Beneficios | €10.45m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.18 |
| Margen bruto | 84.82% |
| Margen de beneficio neto | 33.95% |
| Ratio deuda/patrimonio | 0.5% |
¿Cómo se ha desempeñado B8FE a largo plazo?
Ver rendimiento histórico y comparativa